Table 2 Characteristics of included studies
Study author and year | Study design | Risk of bias | Recruitment period | Study sites and country | Follow-upa(Months or years) | Intervention Nb | TAVI device (%)h | TAVI access (%)h |
|---|---|---|---|---|---|---|---|---|
Reardon 2017 [9] SURTAVI | RCT non-inferiority | Low | 2012–2016 | 87 USA, Canada, and Europe | Max 2 years | TAVI 879 SAVR 867 | Medtronic CoreValve (84) Medtronic Evolut R (16) | TF (NR) TS (NR) TAO (NR) |
Leon 2016 [8] PARTNER 2A | RCT non-inferiority | Low | 2011–2013 | 57 USA and Canada | Max 2 years | TAVI 1011 SAVR 1021 | Edwards SAPIEN XT (100) | TF (76.7) TA (17.2) TAO (6.1) |
Thyregod 2015 [21] NOTION | RCT superiority | Low | 2009–2013 | 2 Denmark, 1 Sweden | Max 5 years | TAVI 145 SAVR 135 | Medtronic CoreValve (100) | TF (96.5) TS (3.5) |
Adams 2014 [7] US CoreValve | RCT non-inferiority and superiority | Low | 2011–2012 | 45 USA | Mean 14.1 months 12.8 months | TAVI 394 SAVR 401 | Medtronic CoreValve (100) | TF (82.8) TS and TAO (17.2) |
Smith 2011 [5] PARTNER A | RCT non-inferiority | Low | 2007–2009 | 22 USA, 2 Canada, 1 Germany | Median 1.4 years | TAVI 348 SAVR 351 | Edwards SAPIEN (100) | TF (70.1) TA (29.9) |
Leon 2010 [4] PARTNER B | RCT superiority | Low | 2007–2009 | 21 (17 USA, 4 other) | Median 1.6 years | TAVI 179 MT 179 (150 MT + BAV) | Edwards SAPIEN (100) | TF (100) |
Repossini 2017 [33] | Observational propensity matched | Low | 2010–2014 | 7 EU | Max 1 month | TAVI 142 SAVR 142 | Edwards SAPIEN XT (NR) Medtronic CoreValve (NR) Symetis ACURATE (NR) | TF (NR) TA (NR) Other transvascular (NR) |
Hannan 2016 [24] | Observational propensity matched | Medium | 2011–2012 | 17 USA | Max 1 year | TAVI 405 SAVR 405 | NR | TF (84.7) TA (15.3) |
D’Onofrio 2016 [23] | Observational propensity matched | Low | 2007–2012 | 33 Italy | Max 1 year | TAVI 214 SAVR 214e | Edwards SAPIEN (NR) Edwards SAPIEN XT (NR) | TF (NR) TA (NR) |
Kobrin 2015 [26] | Observational propensity matched | Low | 2011–2012 | Multicenter USA | Median 6.2 monthsc | TAVI 194 SAVR 194 | NR | NR |
Tamburino 2015 [31] OBSERVANT | Observational propensity matched | Low | 2010–2012 | 93 Italy | Max 1 year | TAVI 650 SAVR 650 | Edwards SAPIEN XT (44.9) Medtronic CoreValve (55.1) | TF (100) |
Schymik 2015 [30] | Observational propensity matched | Low | 2008–2012 2007–2012 | 1 Germany | Max 3 years | TAVI 216 SAVR 216 | Edwards SAPIEN (NR) Edwards SAPIEN XT (NR) Medtronic CoreValve (NR) Symetis ACURATE (NR) | TF (NR) TA (NR) |
Muneretto 2015d [28] | Observational propensity matched | Low | 2007–2014 | 7 Europe | Mean 2.7 years 4.4 years 2.3 years | TAVI 204 SAVR 408f | Edwards SAPIEN XT (38.7) Medtronic CoreValve (59.3) Symetis ACURATE (1.9) | TF (74.5) TA (24.5) Other transvessel approach (0.9) |
Hoffmann 2013 [34] | Observational propensity matched | Low | 2008–2009 | 1 Germany | Max 2 years | TAVI 135 MT 135 (13 MT + BAV) | Edwards SAPIEN (53.3) Medtronic CoreValve (46.7) | TA (53.3) TF (46.7) |
D’Onofrio 2013 [22] | Observational propensity matched | Low | 2008–2011 2009–2011 | Multicenter Italy | Max 1 month | TAVI 143 SAVR 143g | Edwards SAPIEN (NR) Edwards SAPIEN XT (NR) | TA (100) |
Piazza 2013 [29] | Observational propensity matched | Low | 2006–2010 | 3 (Switzerland, Germany, the Netherlands) | Max 1 year | TAVI 405 SAVR 405 | NR | NR |
Latib 2012 [27] | Observational propensity matched | Low | 2007–2011 2003–2008 | 1 Italy | Max 1 year | TAVI 111 SAVR 111 | Edwards SAPIEN and SAPIEN XT (63.1) Medtronic CoreValve (36.9) | TF (100) |
Holzhey 2012 [25] | Observational Propensity matched | Low | 2006–2010 2001–2010 | 1 Germany | Mean 1.8 years | TAVI 167 SAVR 167 | Edwards SAPIEN (100) | TA (100) |
Walther 2010 [32] | Observational propensity matched | Low | 2006–2008 | 1 Germany | Max 1 year | TAVI 100 SAVR 100 | Edwards SAPIEN (100) | TA (100) |